Login to Your Account



Biocardia presses on with Cardiamp pivotal trial to treat HF patients

By Omar Ford
Staff Writer

Tuesday, October 3, 2017

Biocardia Inc. said an independent data safety monitoring board has found there are no safety concerns for the first 10 patients treated in the phase III Cardiamp cell therapy trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription